SPHK1 and metabolic dysfunction-associated steatotic liver disease: Alternatively, research indicates that angiotensin II is a pivotal player in the progression of liver inflammation and fibrosis, with altered TLR4 and sphingosine kinase 1 (SphK1)/sphingosine 1-phosphate (S1P) signaling pathways being key contributors to the pathogenesis of MASLD (77).